

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket Number 21414

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS			
Examiner Initials*	Cite No.	Foreign Patent Document Office Number	Name of Patentee or Applicant of Cited Document Kind Code (if known)
			Date of Publication of Cited Document MM-DD-YYYY
/N.C./	EP 532 456	Ciba Geigy	12/08/1991
	WO 98 31677	Pierre Fabre	07/23/1998
	WO 97 45119	Novartis Ag	12/04/1997
	WO 98 05336	SmithKline Beecham Corporation	02/12/1998
	WO 94 21615	Merck Sharp & Dohme	09/29/1994
	DE 4241632	Dr. Karl Thomas GmbH	06/16/1994
	FR 2758328 (English language abstract)	Pierre Fabre	01/15/1997
	WO 99 51589	Hoechst Schering	03/23/1999
	WO 97 43279	Janssen	11/02/1997
↓/N.C./	FR 2758327 (English language abstract)	Pierre Fabre	01/15/1997

Examiner Signature	/Nizal Chandrakumar/	Date Considered	11/17/2008
--------------------	----------------------	-----------------	------------

***Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer-generated form * IRS Form® (IRS Folder) - Merck & Co., Inc. 12/1/2007

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
Sheet	2	of	2	Examiner Name	
				Attorney Docket Number	21414

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/N.C./		Danysz, W., et al., Pharmacological Rev., Vol. 50, pp. 597-664, 1998
		Dickenson, A., TIPS, Vol. 11, pp. 307-309, 1990
		Wenzel, A., et al., Neurochemistry, Vol. 7, pp. 45-48, 1995
		Kew, J. N. C., et al., Brit. J. Pharmacology, Vol. 123, pp. 463-472, 1998
		Boyce, S., et al., Neuropharmacology, Vol. 38, pp. 611-623, 1999
		Laurie, D. J., et al., Mol. Brain Res., Vol. 51, pp. 23-32, 1997
		Ishii, T., et al., J. Biol. Chem., Vol. 268, pp. 2836-2843, 1993
		Max, M. B., et al., Clin. Neuropharmacology, Vol. 18, pp. 360-368, 1995
		Knox, D. J., et al., Anaesth. Intens. Care, Vol. 23, pp. 620-622, 1995
		Eide, P. K., et al., Pain, Vol. 61, pp. 221-228, 1995
		Kristensen, J. D., et al., Pain, Vol. 51, pp. 249-253, 1992
		Taniguchi, K., et al., Brit. J. Pharmacology, Vol. 122, pp. 809-812, 1997
		Isabelle Parrot, et al., Synthesis of Substituted 3-Amino-6-Arylpyridazines via Suzuki Reaction, Vol. 7, pp. 1163-1168, 1999
↓ /N.C./		J. Moragues, et al., Dopaminergic Activity in a Series of N-substituted 2-Aminopyrimides, Vol. 35, pp. 951-964, 1980

Examiner Signature	/Nizal Chandrakumar/	Date Considered	11/17/2008
--------------------	----------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 12/1/2007